NASDAQ:IMAB - I-Mab Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $78.75
  • Forecasted Upside: 7.27 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.26 (-1.69%)
1 month | 3 months | 12 months
Get New I-Mab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMAB

Average Price Target: $78.75
▲ +7.27% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for I-Mab in the last 3 months. The average price target is $78.75, with a high forecast of $90.00 and a low forecast of $75.00. The average price target represents a 7.27% upside from the last price of $73.41.


The current consensus among 5 contributing investment analysts is to buy stock in I-Mab.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$76.00 ➝ $90.00High
6/2/2021Daiwa Capital MarketsInitiated CoverageBuyHigh
3/30/2021HC WainwrightReiterated RatingBuyMedium
3/15/2021Needham & Company LLCInitiated CoverageBuy$75.00Medium
3/3/2021HC WainwrightBoost Price TargetBuy$55.00 ➝ $75.00Low
2/25/2021Piper SandlerInitiated CoverageOverweight$75.00High
12/7/2020HC WainwrightInitiated CoverageBuy$55.00High
9/8/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$50.00 ➝ $55.00High
9/1/2020Cantor FitzgeraldReiterated RatingOverweightMedium
7/27/2020Cantor FitzgeraldInitiated CoverageOverweight$50.00High
2/13/2020CICC ResearchInitiated CoverageOutperform$18.09Low
2/12/2020China Renaissance SecuritiesInitiated CoverageBuy$17.93Low
2/11/2020Jefferies Financial GroupInitiated CoverageBuy$16.00Low
(Data available from 6/20/2016 forward)
I-Mab logo
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Read More

Today's Range

Now: $73.41
Low: $72.69
High: $75.16

50 Day Range

MA: $65.86
Low: $47.86
High: $81.07

52 Week Range

Now: $73.41
Low: $26.02
High: $84.01


694,244 shs

Average Volume

467,165 shs

Market Capitalization

$5.32 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of I-Mab?

The following Wall Street sell-side analysts have issued stock ratings on I-Mab in the last twelve months: Cantor Fitzgerald, Daiwa Capital Markets, HC Wainwright, Needham & Company LLC, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for IMAB.

What is the current price target for I-Mab?

4 Wall Street analysts have set twelve-month price targets for I-Mab in the last year. Their average twelve-month price target is $78.75, suggesting a possible upside of 7.3%. Cantor Fitzgerald has the highest price target set, predicting IMAB will reach $90.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $75.00 for I-Mab in the next year.
View the latest price targets for IMAB.

What is the current consensus analyst rating for I-Mab?

I-Mab currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMAB will outperform the market and that investors should add to their positions of I-Mab.
View the latest ratings for IMAB.

What other companies compete with I-Mab?

How do I contact I-Mab's investor relations team?

I-Mab's physical mailing address is SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT, SHANGHAI F4, 201210. The company's listed phone number is 86-21-6057-8000 and its investor relations email address is [email protected] The official website for I-Mab is